CRISPR genome-editing grows up: advanced therapies head for the clinicGene-editing technologies for cancer and blood disorders are maturing a little more than a year after the first CRISPR drug was approved.NatureHeidi Ledford
Study Failure Spotlights Challenges for ctDNA Strategies in Breast Cancer Drug Trials
Researchers stopped a Phase III